Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
-0.68% $1.947
/ 21 sep 2022 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 14.47 mill |
EPS: | -3.97 |
P/E: | -0.491 |
Earnings Date: | Mar 29, 2023 |
SharesOutstanding: | 7.43 mill |
Avg Daily Volume: | 0 mill |
RATING 2022-11-22 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.491 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.491 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.813 - 2.11 ( +/- 7.50%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-07-18 | Le Goff Corinne | Buy | 177 000 | Stock Option (Right to Buy) |
2022-07-18 | Le Goff Corinne | Sell | 0 | Common Stock |
2022-06-13 | Kardaras Constantine John | Buy | 1 750 | Option to Purchase Celsion Common Stock |
2022-06-13 | Tumminello Timothy J | Buy | 7 500 | Option to Purchase Celsion Common Stock |
2022-06-13 | Chow Pok Yu Augustine | Buy | 7 500 | Option to Purchase Celsion Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 4 307 000 | Sell: 1 490 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.947 (-0.68% ) |
Volume | 0.0568 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.